Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

Dallas, Texas–(Newsfile Corp. – May 19, 2025) – Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget. Early clinician and patient feedback has been positive, citing successful initial patient outcomes and strong ordering momentum, with rapid product replenishment by wholesalers. The field team reported broad engagement across high-priority LTC accounts nationwide. Importantly, Medicare reimbursement was secured soon after launch, significantly improving access for patients in LTC settings. Management reiterated that all launch objectives remain on track and within budget, with commercial execution progressing as planned.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Officially launched ZUNVEYL to US market in March, 2025.

• The Company secured a new composition of matter patent in the U.S., covering the tablet formulation of benzgalantamine.

• ZUNVEYL net product revenues of $0.35M; with licensing revenue of $2.6M.

Click image above to view full announcement.

---

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252571